On December 25, 2019, the Pharmaceutical Business Branch of the All-China Federation of Industry and Commerce Medical Chamber of Commerce held the “2018 National 100 Outstanding Private Pharmaceutical Commercial Circulation Enterprises List Conference” in Xi ‘an, Shaanxi Province. Venturepharma Pharmaceutical was honored with two awards: “Top 100 Outstanding Private Pharmaceutical Commercial Circulation Enterprises in China in 2018” and “Best Service Provider of Pharmaceutical Supply Chain Logistics in 2018”.
Mr. Guo Xia, chairman of the company, won the title of “Top Ten Annual Figures of private Pharmaceutical Business”, and Ms. Song Xuemei, vice chairman of the company also won the honorary title of “2018 annual figures of Private Pharmaceutical Business expansion”.
Combined with years of accumulated experience and abundant industry resources, the Pharmaceutical Business Branch of the All-China Federation of Industry and Commerce Medical Chamber of Commerce invited domestic first-class experts to form a selection panel, adhering to the principles of open solicitation, objective data, strict screening and fair selection, and launched a series of solicitation and evaluation activities to select the “2018 National 100 Outstanding Private Pharmaceutical Commercial Distribution Enterprises List”.
Say goodbye to close friends and start “Venturepharma”
In the late 1990s, Guo Xia said goodbye to his best friend and mentor and started his entrepreneurial journey. At the beginning of his business venture, Guo Xia was filled with hardships and trials. However, he never thought of giving up. In his mind, there was only one thought: only by withstanding the wind and rain can one see the function of “Venturepharma”.
During that period, Guo Xia shuttled back and forth both at home and abroad. His average flight records of over two hundred times a year bear witness to the efforts and hardships he has made on the path of pioneering “Venturepharma”.
Today, Venturepharma is at the forefront of new drug research and development in China, with R&D and service institutions distributed all over the world. Under the leadership of Mr. Guo Xia, Venturepharma Technology Pharmaceutical has been supporting the smooth progress of new drug research and development through commercial operation. Its unique business model not only differs from traditional research institutions but also lays a solid foundation for the industrialization of research results.
At present, the company’s diversified income comes from technology transfer (including installment payment and drug sales commission after marketing), pharmaceutical research and development service income, and clinical research service income. The company provides new drug technology for domestic and foreign pharmaceutical enterprises, and has established a good long-term cooperative relationship with many large domestic pharmaceutical enterprises. Its subsidiary, Dezhong Venturepharma, is committed to rapidly becoming the top drug research and development company in Asia. Sunshine Venturepharma has become one of the earliest and most outstanding clinical research companies in China, participating in and leading over 20 national 973 innovation projects during the 12th and 13th Five-Year Plans.
The fundamental source of all innovation is whether it can cure diseases, really cure patients’ diseases, this is really valuable.
Dezhong Venturepharma, the R&D flagship of Venturepharma in China, has eight global R&D centers, spanning four continents and distributed in six countries. The research and development variety involves a wide range of fields, the research and development of new drugs ranks in the top, and thousands of patents have been applied.
Thanks to China brain science, heart and brain double happiness, many product developers and national major scientific research participation organizers, and then the national major new drug creation, science and technology innovation project approval.
These seven products in the field of neuroscience and psychiatry will bring a market of 10 billion dollars and rewrite the name of the brain science. In the first human disability disease, mental health disorders, providing schizophrenia, bipolar and anxiety disorders, sleep, epilepsy and other diseases treatment drugs.
With our innovative Venturepharma skills, we have developed over 500 new Chinese-style drugs and applied for thousands of patents.
For the enterprise to lay a good foundation.
Venturepharma is committed to providing patients with affordable and accessible good medicine. Saving lives and bringing health to the people is the ultimate mission of Venturepharma Medicine.
Venturepharma was founded in 1998, and the numerous top-notch pharmaceutical technologies it has established are applied to drug innovation
In the practice of reinnovation, we are committed to making the Chinese people enjoy and afford the world’s most advanced drugs and the pursuit of health and beauty, and have an extraordinary impact on the improvement of China’s health.
The most innovative enterprise in China’s health industry
Led China’s new drug research and development for 11 years, and ranked first in China’s new drug application for 10 years —
SFDA Statistics
Create a vertically integrated business model driven by three
About the Unit
Create Wandema franchise alliance marketing model
Venturepharma R&D: In line with the world’s leading standards, leading China’s pharmaceutical R&D.
Venturepharma Sunshine: With 386 research bases across the country, it is one of the largest and most authoritative international contract research organizations (CROs) in the field of clinical research in China.
Wante Pharmaceutical: As the largest production base of Venturepharma Pharmaceutical Group, it aims to build a leading pharmaceutical processing industry in China
Industry flagship, create the largest pharmaceutical export production base in the Far East region!
Wandema Marketing: Through the franchise mode of operation, to create the “Wal-Mart” of the Chinese medical industry.